Argenx
ARGX
#495
Rank
โ‚ฌ43.21 B
Marketcap
691,49ย โ‚ฌ
Share price
0.81%
Change (1 day)
35.49%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Annual Reports (20-F)

Latest form 20-F annual reports for Argenx CIK: 0001697862
The 20-F is a 10-K equivalent for non-US companies, as a foreight company Argenx only files 20-F reports

Thumbnail Argenx
 20-F Annual Report

20-F Annual Report 2026-03-19

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report

20-F Annual Report 2025-03-20

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report

20-F Annual Report 2024-03-21

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report

20-F Annual Report 2023-03-16

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report

20-F Annual Report 2022-03-21

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report

20-F Annual Report 2021-03-30

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report

20-F Annual Report 2020-03-31

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report

20-F Annual Report 2019-03-26

Language: English

View Annual Report (20-F)
Thumbnail Argenx
 20-F Annual Report

20-F Annual Report 2018-03-26

Language: English

View Annual Report (20-F)